Condition

CLL clinical trials and research

• 14Clinical trials
• 31Countries

Newest CLL clinical trials

All recruiting trials (14)

• Rocbrutinib versus pirtobrutinib for adults with relapsed or refractory CLL/SLL after a covalent BTK inhibitor

  This compares rocbrutinib and pirtobrutinib to see which works better and is safer for adults whose CLL or SLL returned or didn't respond after a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Newave Pharmaceutical Inc · Skokie, Illinois and 6 other locations · NCT07342478

• BAFF-R CAR-T therapy for relapsed or refractory BAFF-R–positive B-cell lymphoma

  This trial will test whether a BAFF‑R–targeted CAR‑T cell therapy is safe and can help adults with relapsed or refractory BAFF‑R–positive B‑cell lymphomas (such as DLBCL, CLL, FL, MCL, or WM).

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07259070

• Anti‑CD19 CAR‑T plus a BTK inhibitor for newly diagnosed high‑risk CLL/SLL

  We will try combining anti‑CD19 CAR‑T cells with a BTK inhibitor as first‑line treatment for people newly diagnosed with high‑risk CLL or SLL.

  Recruiting The Affiliated Hospital of Xuzhou Medical University · Xuzhou, Jiangsu · NCT07120633

• Epcoritamab given after 2nd-generation BTK inhibitors for CLL/SLL

  This trial will try giving subcutaneous epcoritamab for up to 12 cycles to adults with CLL/SLL who have been on a second‑generation BTK inhibitor for at least 12 months to see if it can deepen responses to a complete remission with undetectable MRD so therapy can be stopped.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07108998

• Finding the right dose of MB-CART2219.1 CAR‑T (targets CD19 and CD22) for relapsed B‑cell cancers

  This trial will test MB‑CART2219.1, a CAR‑T cell therapy that targets CD19 and CD22, in adults and children with relapsed or refractory B‑cell cancers to find a safe dose.

  Recruiting Phase 1 University Hospital Tuebingen · Tübingen, Baden-Wurttemberg and 1 other locations · NCT07108868

• Comparing BGB-16673 to standard treatments for chronic lymphocytic leukemia

  This study is testing a new treatment called BGB-16673 to see if it works better than standard options for people with chronic lymphocytic leukemia who have already tried other therapies.

  Recruiting at 132 sites Phase 3 BeOne Medicines · Jonesboro, Arkansas and 131 other locations · NCT06846671

• Investigating a new dosing schedule for sonrotoclax in blood cancer treatment

  This study is testing new ways to give the drug sonrotoclax to see if it can safely help people with chronic lymphocytic leukemia (CLL) feel better.

  Recruiting at 22 sites Phase 1/2 BeOne Medicines · Tampa, Florida and 21 other locations · NCT06697184

• Testing KLS-1 for treating certain cancers

  This study is testing a new drug called KLS-1 to see if it can safely help adults with certain types of cancer, including solid tumors and chronic lymphocytic leukemia.

  Recruiting at 2 sites Phase 1/2 Vector Vitale LLC · Kropyvnytskyi and 1 other locations · NCT06506643

• Comparing two treatments for relapsed chronic lymphocytic leukemia

  This study is testing if a new combination of two drugs, nemtabrutinib and venetoclax, can help people with relapsed chronic lymphocytic leukemia live longer without their cancer getting worse compared to the usual treatment.

  Recruiting at 103 sites Phase 3 Merck Sharp & Dohme LLC · Springdale, Arkansas and 105 other locations · NCT05947851

• Using CARCIK-CD19 cells to treat B-cell cancers in adults and children

  This study is testing a new type of cell treatment for adults and children with certain B-cell cancers to see if it is safe and effective for those who can't use existing therapies.

  Recruiting Phase 1/2 Fondazione Matilde Tettamanti Menotti De Marchi Onlus · Bergamo, BG · NCT05869279

• Metabolism in the Lymphatic Niche of CLL

  This study looks at how the lymphatic environment affects metabolism in people with chronic lymphocytic leukemia (CLL) to see if it influences disease behavior.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice · NCT05610228

• Understanding resistance to venetoclax in chronic lymphocytic leukemia

  This study is trying to understand why some patients with chronic lymphocytic leukemia don’t respond to the treatment venetoclax by looking at their medical information and samples.

  Recruiting University Hospital, Clermont-Ferrand · Amiens and 13 other locations · NCT05246345

• Combination treatment for newly diagnosed CLL patients at high risk of infection

  This study is testing a combination of two cancer drugs to see if it can help newly diagnosed CLL patients who are at high risk of infections stay infection-free before they need chemotherapy.

  Recruiting at 7 sites Phase 2/3 Copenhagen University Hospital, Rigshospitalet · Copenhagen and 6 other locations · NCT03868722

• Registry for patients with chronic lymphocytic leukemia and related conditions

  This study is tracking patients with chronic lymphocytic leukemia and similar conditions to see how well different treatments work and what long-term effects they might have.

  Recruiting German CLL Study Group · Dresden, Saxony · NCT02863692

Related topics

Quick answers

How many CLL clinical trials are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 31 countries. The most sites are in United States (5 trials), France (4 trials), Germany (4 trials), China (3 trials), Italy (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 4, Phase 3: 3, Phase 1: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →